University of Texas/MD Anderson Cancer Center MD LDEX2104
Welcome,         Profile    Billing    Logout  
 4 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Puduvalli, Vinay K
NCT02337686: Pembrolizumab in Treating Patients With Recurrent Glioblastoma

Active, not recruiting
2
18
US
Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pharmacological Study, Therapeutic Conventional Surgery
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Glioblastoma, Recurrent Gliosarcoma
05/17
12/26
NCT05879120: Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma

Withdrawn
2
10
US
Pembrolizumab, Keytruda, MK-3475, SCH-900475, Exablate MRgFUS + neoadjuvant pembolizumab
M.D. Anderson Cancer Center, InSightec, Merck Sharp & Dohme LLC
Recurrent Glioblastoma
10/24
10/24
NCT00555399: Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Terminated
1/2
55
US
Vorinostat, SAHA, Suberoylanilide Hydroxamic Acid, MSK-390, Zolinza, Isotretinoin, cRA, Accutane, 13-cis-Retinoic Acid, Surgical Resection, Temozolomide, Temodar
M.D. Anderson Cancer Center, Merck Sharp & Dohme LLC
Glioblastoma Multiforme, Anaplastic Glioma
01/20
01/20
NCT03382977: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Recruiting
1/2
98
US
VBI-1901, Carmustine, BiCNU, Lomustine, Gleostine
VBI Vaccines Inc.
Glioblastoma Multiforme
07/25
08/25
NCT00102648: Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide

Active, not recruiting
1
34
US
Lonafarnib, 4-[2-[4-[(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide, Sarasar, SCH 66336, SCH-66336, SCH66336, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Malignant Supratentorial Neoplasm, Recurrent Glioblastoma, Recurrent Gliosarcoma
03/25
12/25
NCT01430351: Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy

Active, not recruiting
1
144
US
Mefloquine, Memantine Hydrochloride, Ebixia, Namenda, Metformin Hydrochloride, APO-Metformin, Cidophage, Dimefor, Glifage, Glucoformin, Glucophage, Glucophage ER, Metformin HCl, Riomet, Siofor, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
09/25
09/25

Download Options